These findings suggest that enhancing ALDH2 function—through pharmacological activators or gene therapy—may provide a viable approach for mitigating DCM and other ALDH2-related cardiovascular complications in human populations. Here, ALDH2 is linked to familial dilated cardiomyopathy.